A Role for K-ras in Conferring Resistance to the MEK Inhibitor, CI-1040
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
PD184352/CI-1040 is a potent and selective MEK1/2 inhibitor that represents the first MEK-targeted agent to enter clinical trials. Here, we report the development and molecular characterization of CI-1040 resistance in the murine colon 26 (C26) carcinoma cell line. The growth rate of the resistant line (C26/CI-1040r) in the presence of 2 microM CI-1040 is comparable to that of parental C26 cells in the absence of CI-1040. C26/CI-1040r cells are approximately 100-fold more resistant than the parental line to CI-1040 inhibition in soft agar and are less sensitive to the induction of apoptosis that normally occurs in response to CI-1040 treatment. K-ras expression is significantly elevated in C26/CI-1040r cells. We confirmed a causative role for K-ras in conferring resistance to CI-1040 by transfecting K-ras into parental C26 cells, whereupon an elevation in the levels of phosphorylated ERK1/2 was observed in addition to resistance to CI-1040. Furthermore, an in vivo-derived MEK inhibitor-resistant line also shows increased K-ras expression. Our data suggest that increasing activated K-ras expression represents one potential mechanism by which tumor cells that initially are responsive to blockade of the MAP kinase pathway can overcome their sensitivity to MEK inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“tion and instead induces cellular senescence [22].”
Cited by
Targeting the RAF–MEK–ERK pathway in cancer therapy
Montagut, C., & Settleman, J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.022 · Cited by 468
Ras oncogenes and their downstream targets
Rajalingam, K., Schreck, R., Rapp, U. R., & Albert, Š. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.01.012 · Cited by 458
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
Paraiso, K. H. T., Fedorenko, I. V., Cantini, L. P., Munko, A. C., Hall, M., Sondak, V. K., Messina, J. L., Flaherty, K. T., & Smalley, K. S. M. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605714 · Cited by 314
“In non-melanoma systems, chronic treatment with the MEK inhibitor CI-1040 leads to resistance associated with increased KRAS and MEK expression (”
BackgroundMechanisms of drug inhibition of signalling molecules
Sebolt-Leopold, J. S., & English, J. M. (2006) · Nature · doi:10.1038/nature04874 · Cited by 304
Self-citationIshii, N., Harada, N., Joseph, E. W., Ohara, K., Miura, T., Sakamoto, H., Matsuda, Y., Tomii, Y., Tachibana-Kondo, Y., Iikura, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3937 · Cited by 179
Metadata
- Authors
- Wangab, Y., Van Becelaere, K., Jiang, P., Przybranowski, S., Omer, C., & Sebolt-Leopold, J.
- Venue
- Neoplasia
- Publisher
- Elsevier BV
- Published
- 2005-04
- Volume
- 7
- Issue
- 4
- Pages
- 336-347
- ISSN
- 1476-5586 (ISSN-L)
- OpenAlex
- W2074867181
- Cited by
- 53
- References
- 1
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.